Research ExplorerPublicationsTreatment of imported severe malaria with artesunate instead...

Treatment of imported severe malaria with artesunate instead of quinine--more evidence needed?

Standard

Treatment of imported severe malaria with artesunate instead of quinine--more evidence needed? / Cramer, Jakob; López-Vélez, Rogelio; Burchard, Gerd-Dieter; Grobusch, Martin P; Vries, de; Peter, J.

In: MALARIA J, Vol. 10, 2011, p. 256.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Cramer, J, López-Vélez, R, Burchard, G-D, Grobusch, MP, Vries, D & Peter, J 2011, 'Treatment of imported severe malaria with artesunate instead of quinine--more evidence needed?', MALARIA J, vol. 10, pp. 256. https://doi.org/10.1186/1475-2875-10-256

APA

Cramer, J., López-Vélez, R., Burchard, G-D., Grobusch, M. P., Vries, D., & Peter, J. (2011). Treatment of imported severe malaria with artesunate instead of quinine--more evidence needed? MALARIA J, 10, 256. https://doi.org/10.1186/1475-2875-10-256

Vancouver

Cramer J, López-Vélez R, Burchard G-D, Grobusch MP, Vries D, Peter J. Treatment of imported severe malaria with artesunate instead of quinine--more evidence needed? MALARIA J. 2011;10:256. https://doi.org/10.1186/1475-2875-10-256

Bibtex

@article{02b46672c5574d08a739971974f4a2dd,
title = "Treatment of imported severe malaria with artesunate instead of quinine--more evidence needed?",
abstract = "Rapid and fast acting anti-malarials are essential to treat severe malaria. Quinine has been the only option for parenteral therapy until recently. While current evidence shows that intravenous artesunate is more effective than quinine in treating severe malaria in endemic countries, some questions remain regarding safety profiles and drug resistance. For imported severe malaria, additional unanswered questions are related to generalizability of the findings from endemic countries and to legal aspects, as there is no Good Manufacturing Practice-conform drug available yet. Here, the implications of existing evidence for the treatment of imported severe malaria are discussed.",
keywords = "Humans, Injections, Intravenous, Antimalarials/*administration & dosage, Artemisinins/*administration & dosage/adverse effects, Malaria/*drug therapy, Quinine/administration & dosage, Humans, Injections, Intravenous, Antimalarials/*administration & dosage, Artemisinins/*administration & dosage/adverse effects, Malaria/*drug therapy, Quinine/administration & dosage",
author = "Jakob Cramer and Rogelio L{\'o}pez-V{\'e}lez and Gerd-Dieter Burchard and Grobusch, {Martin P} and de Vries and J Peter",
year = "2011",
doi = "10.1186/1475-2875-10-256",
language = "English",
volume = "10",
pages = "256",
journal = "MALARIA J",
issn = "1475-2875",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Treatment of imported severe malaria with artesunate instead of quinine--more evidence needed?

AU - Cramer, Jakob

AU - López-Vélez, Rogelio

AU - Burchard, Gerd-Dieter

AU - Grobusch, Martin P

AU - Vries, de

AU - Peter, J

PY - 2011

Y1 - 2011

N2 - Rapid and fast acting anti-malarials are essential to treat severe malaria. Quinine has been the only option for parenteral therapy until recently. While current evidence shows that intravenous artesunate is more effective than quinine in treating severe malaria in endemic countries, some questions remain regarding safety profiles and drug resistance. For imported severe malaria, additional unanswered questions are related to generalizability of the findings from endemic countries and to legal aspects, as there is no Good Manufacturing Practice-conform drug available yet. Here, the implications of existing evidence for the treatment of imported severe malaria are discussed.

AB - Rapid and fast acting anti-malarials are essential to treat severe malaria. Quinine has been the only option for parenteral therapy until recently. While current evidence shows that intravenous artesunate is more effective than quinine in treating severe malaria in endemic countries, some questions remain regarding safety profiles and drug resistance. For imported severe malaria, additional unanswered questions are related to generalizability of the findings from endemic countries and to legal aspects, as there is no Good Manufacturing Practice-conform drug available yet. Here, the implications of existing evidence for the treatment of imported severe malaria are discussed.

KW - Humans

KW - Injections, Intravenous

KW - Antimalarials/administration & dosage

KW - Artemisinins/administration & dosage/adverse effects

KW - Malaria/drug therapy

KW - Quinine/administration & dosage

KW - Humans

KW - Injections, Intravenous

KW - Antimalarials/administration & dosage

KW - Artemisinins/administration & dosage/adverse effects

KW - Malaria/drug therapy

KW - Quinine/administration & dosage

U2 - 10.1186/1475-2875-10-256

DO - 10.1186/1475-2875-10-256

M3 - SCORING: Journal article

VL - 10

SP - 256

JO - MALARIA J

JF - MALARIA J

SN - 1475-2875

ER -